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Abstract 
Background: Locally advanced breast cancer (LABC) is common in developing countries and it frequently affects younger women. 
Patients do very poorly when treated by locoregional therapy alone; therefore, pre-operative systemic therapy (PST) is commonly used.  
Materials and methods: Medical records of 64 Saudi patients with LABC treated with PST in a single institution were retrospectively 
reviewed.  
Results: At diagnosis, most patients were young (median age 41 years), and had poor clinicopathological characteristics. Following 
surgery, complete pathologic response (pCR) in the breast was achieved in 13 patients (20%). Of 62 patients with known nodal status, 
22 (34%) had negative axillary nodes. Presence of oestrogen receptor (ER) negative tumour was the only dependent variable that 
predicted pCR in the breast (p = 0.03). At a median follow-up of 42 months, the median progression-free survival (PFS) was 48 months 
(95% CI, 20–76 months) and the projected five-year overall survival (OS) was 68%. The recently published scoring system (Jeruss et al 
(2008) J Clin Oncol 26 2 246–52), was the only variable that independently influenced PFS, while ER negative tumours and presence of 
lymphovascular space invasion were the only factors that adversely affected OS. 
Conclusions: despite the use of standard multi-modality approach in the management of patients with LABC, prognosis remains 
guarded. 
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Introduction 
Pre-operative systemic therapy (PST), initially used only for 
locally advanced breast cancer (LABC), has become more 
common for patients with operable disease [1–3]. In patients 
with operable breast cancer, randomized trials have 
demonstrated that PST and post-operative chemotherapy 
(using the identical agents and treatment schedules) result in 
the same disease-free (DFS) and overall survival (OS) [4]. It 
has also been shown that long-term outcome significantly 
correlates with both clinical and pathologic tumour response 
rates [5,6]. 
Recently, researchers at MD Anderson Cancer Center have 
developed scoring systems based on combined clinical and 
pathologic variables to define outcome for breast cancer 
patients treated with PST [7]. The study population was 
composed of 932 patients that were predominantly post- or 
perimenopausal with a median age of 50 years. The series 
included patients with LABC as well as patients with small 
primary tumour. In brief, the scoring systems assigned risk 
scores to clinical stage, pathologic stage, oestrogen receptor 
(ER) negative tumour, and grade III disease. A combined 
prognostic score ranging from 0 to 6 was developed (the higher 
score the worse was the prognosis). The study concluded that 
the scoring systems facilitated separation of the study 
population into more refined subgroups by outcome than the 
current staging system. 
In Saudi Arabia like other developing countries, LABC is not 
only common but it also affects women at a much younger age, 
and it carries a distinctively poor outcome [8–11]. 
The primary objective of the current study was to describe the 
clinicopathologic features and to determine the outcome of 
patients with LABC treated in a single institution with PST. We 
also intended to test the utility of MD Anderson Cancer Center 
scoring systems in our patient population. 
 
Patients and methods 
This retrospective study was approved by the Institutional 
Review Board of the King Faisal Specialist Hospital and 
Research Center. Data of newly diagnosed consecutive patients 
with locally advanced non-inflammatory invasive breast cancer 
(T2 > 4 cm, T3 or T4) confirmed on tru-cut biopsy and who 
received PST, were retrospectively reviewed. The database 
was locked on March 2009. Those with bilateral breast cancer, 
or documented evidence of metastatic disease, were excluded. 
Staging procedures included complete history and physical 
examination, laboratory studies, bilateral mammography and 
mammary ultrasound, computerized tomography of the chest 
and abdomen, and radionuclide bone scan. ER and 
progesterone receptors (PR) were measured using standard 
immunehistochemistry (IHC), and the positive score was 
defined as greater than or equal to 10% of tumour cells 
demonstrating nuclear staining. HER-2 was graded as per the 
Dako HercepTest (Dako, Carpinteria, CA). For Her-2 +2 by IHC, 
HER-2 gene amplification was assessed by fluorescent in situ 
hybridization (FISH), using the Vysis method (Abbott Molecular, 
Inc., Des Plaines, IL). HER-2 positive tumours were those 
scoring 3+ by IHC or with > two copies of the HER-2 gene by 
FISH assay. 
Clinical size of primary breast cancers and axillary nodes, if the 
latter were palpable, was determined separately before the 
administration of each cycle of PST and also before surgery. At 
each assessment, the product of the two greatest perpendicular 
diameters of the tumours in the breast and axilla was measured. 
Assessment of response was determined by clinical 
examination combined with mammography and 
ultrasonography. Women with dense breasts were also 
evaluated by magnetic resonance imaging. 
 
Therapy 
Patients received various PST regimens at the discretion of the 
treating physician. Following the PST regimen, response was 
assessed both clinically and by repeating relevant imaging. 
Patients with minimal or no response after two to three cycles 
were considered for alternative chemotherapy regimens. After 
the last cycle, patients were scheduled to undergo conservative 
surgery or modified radical mastectomy upon discretion of the 
surgeon and according to patient preference guided by the 
clinical response. Axillary lymph node dissection to levels I and 
II, aiming for excision of at least ten lymph nodes, was to be 
performed. 
While most patients received post-surgery radiotherapy to the 
chest wall or the conserved breast and the axilla, post-operative 
adjuvant chemotherapy or hormonal therapy was given 
according to the discretion of the oncologist guided by the 
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Statistical methods  pathological response and the relevant clinicopathological 
characteristics. 
A two-sided Wilcoxon-Pratt test was used to compare tumour 
sizes before and after chemotherapy. To identify variables that 
predict pCR in the primary tumour, regression analysis was 
performed [18]. Overall survival (OS) was estimated from the 
date of starting PST to the date of last follow-up or death from 
any cause. Progression-free survival (PFS) was calculated from 
the date of definitive surgery until last contact; recurrence 'local, 
regional or distant'; occurrence of contralateral breast cancer; 
occurrence of second primary cancer other than in the 
contralateral breast or death. Survival was estimated by 
applying the method of Kaplan and Meier [19], while the 
statistical procedure of Brookmeyer-Crowley was used to 
estimate the 95% confidence interval (CI) of median survival 
[20]. The log-rank test was used to assess the significance of 
unadjusted differences in survival [21]. Exploring variables for 
their independent prognostic effect on OS or PFS was carried 
out using the multivariate stepwise regression model of Cox and 
Oakes to compute hazards ratio (HR) [22]. Being one of the 
objectives of our study, we specifically examined the prognostic 
significance of the scoring system as reported by Jeruss et al 
and alluded to in the introduction [7]. In the survival analysis, we 
grouped patients according to their assigned risk score. 
Variables with p value • 0.1 in the univariate analysis were 
tested for the multivariate model. In this process, the predictor 
with the highest level of statistical significance was used to 
introduce the model; other variables were then evaluated for 
further predictive information and added in turn, beginning with 
the variables with the highest level of statistical significance (i.e. 
the lowest p values) and continuing until the p value for the 
variable added exceeded 0.05. Continuous prognostic variables 
were also considered for inclusion in the model as dichotomous 
variables using various cut-off points only if they attained a p 
value of • 0.1 in the univariate analysis. We also compared the 
survival functions for variables after stratifying for baseline 
differences in additional variables [23]. All tests of significance 
were two sided, and differences were considered statistically 
significant when P <0.05. We performed all data analyses using 
the SPSS Statistical Software Package (SPSS software v. 17.0; 
SPSS Inc., Chicago, IL, USA). 
Data source 
A computerized database was created to capture hardcopy and 
electronic patient data. The following information was retrieved: 
patients' demographic and clinical data, laboratory and 
radiological studies, disease characteristics and PST details 
including clinical response and toxicity. The database also 
included surgery details, axillary lymph node dissection and 
pathologic response. Also, captured were post-surgery further 
chemotherapy, hormonal therapy, radiation therapy, recurrence 
and survival. 
 
Definitions 
Staging was defined according to the criteria determined by the 
International Union Against Cancer (UICC) [12], with group 
clinical and pathological staging according to the American Joint 
Committee on Cancer [13]. We adopted the criteria for LABC 
reported by Haagensen and Stout [14]. Best clinical response 
was assessed by physical and radiological examination and 
defined as complete response (cCR), partial response (cPR), 
stable disease (cSD), and progressive disease (cPD) according 
to response evaluation criteria in solid tumours [15]. This 
classification was also used to record the response of an 
axillary tumour to the PST regimen in patients who had clinically 
positive nodes at diagnosis. The development of a clinically 
suspicious ipsilateral axillary tumour during chemotherapy was 
considered as evidence of cPD in patients whose axilla was 
clinically negative when the first cycle of the PST was 
administered. 
 
Histopathology 
A median of 15 sections of the mastectomy or lumpectomy 
specimen was assessed; these included sections from each 
quadrant, from the nipple–areola complex (if appropriate), from 
areas of suspicious or prior tumour involvement and from the 
axillary contents (median of seven sections). 
Pathologic response was assessed in surgical specimens of 
mammary tissue and lymph nodes using Sataloff et al [16] and 
Chevallier  et al [17] criteria. Complete pathological response 
(pCR) in the breast, was defined as disappearance of invasive 
disease in the breast by pathologic examination, while residual 
invasive disease of < 1 cm and • 1 cm was considered for 
descriptive purpose only as micro- and macro-residual disease, 
respectively. pCR in axilla was defined as absence of positive 
lymph nodes by haematoxylin and eosin staining. 
 
Results 
This retrospective analysis included the records of 64 patients, 
and they were all evaluable for efficacy and toxicity analysis. 
The median age was 41 years (range, 25–75). Patient and 
disease characteristics are depicted in Table 1. The median
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Table 1: Patient and disease characteristics (64 patients)  
 4  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:161 
 
  
Table 2: Neoadjuvant and adjuvant therapy 
largest tumour diameter at diagnosis was 7.5 cm (range, 2–15 
cm). Four (6%) and 60 (94%) patients had invasive lobular and 
invasive ductal cancer, respectively. 
Table 2 shows the PST regimens and the adjuvant treatment 
given. Due to minimal or no response to initial anthracycline-
based therapy, four patients required substitution of PST by 
taxane-platinum-based regimens. The median time from 
diagnosis to the initiation of PST was 24 days (95% CI, 32–69 
days), and the median number of PST cycles was four (range, 
2–8). Patients with HER-2 over-expression (seven patients) 
received neoadjuvant trastuzumab concomitantly with 
chemotherapy according to the MD Anderson protocol [7]. 
All patients were evaluable for the best clinical response (BCR). 
According to the pre-defined criteria, 18 (28%), 31 (48%), nine  
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Table 3: Relationship between pathologic responses of the primary tumour versus pathologic nodal status 
(14%) and six (10%) of the patients achieved cCR, cPR, cSD 
and cPD, respectively. The median time to the best clinical 
response was 2.7 months (95% CI, 2.6–4.6 months). 
Following PST, patients underwent surgery (Table 2). The 
median time from starting therapy to surgery was 4.2 months 
(95% CI, 4–5.8 months). Despite a combined cCR and cPR rate 
of 76%, only 26 patients (41%) had conservative surgery. The 
pathologic response in the primary tumour was considered 
complete (pCR) in 13 (20%) of patients. On the other hand, 
residual invasive disease was microscopic (< 1 cm in diameter) 
and macroscopic (• 1 cm in diameter), in 18 (28%) and 33 
(52%) patients, respectively. The median largest residual 
tumour diameter was 1.8 cm (range, 0–8). Compared with 
baseline assessment that downstaging was statistically 
significant (Table 3 depicts the pathologic data for the primary 
tumour and axillary lymph nodes. Of all 64 patients, eight (13%) 
achieved pCR in the primary tumour and in the axilla. None of 
the eight patients had residual non-invasive disease. The main 
clinicopathologic features of those eight patients were as 
follows: six patients (75%) were • 50 years; four patients (50%) 
each had clinical stage IIB and IIIA, respectively; tumour grade 
II/III in 2/6 patients; lymphovascular space invasion -
ve/unknown in 6/2 patients; ER+/ER- in 3/5 patients; PR+/PR- 
in 1/7 patients; and HER-2+/HER-2- in 4/4 patients. ER negative 
tumour was the only variable that independently predicted pCR 
in the breast (p = 0.03). 
Seven patients who over-expressed HER-2 received 
neoadjuvant trastuzumab. Three patients achieved pCR in the 
primary tumour and the axilla. Two patients attained pCR in the 
primary tumour but with one positive lymph node in each 
patient. Of the remaining two patients, one had micro-residual 
disease and one had macro-residual disease. Neither of the 
latter two patients had positive axillary disease. 
 
Survival analysis 
At a median follow-up of 42 months (95% CI, 34–49 months), 
13 patients (20%) were dead, 15 (24%) were alive with 
evidence of disease and the remaining 35 (56%) were still alive 
with no apparent evidence of disease. All mortality events were 
attributed to progressive breast cancer or its related 
complications. 
Disease recurrence was documented in 29 patients (45%). The 
first documented recurrence was local and/or regional, 
contralateral breast, contralateral lymph nodes, distant, distant 
and locoregional, in five, three, two, 18 and one patients, 
respectively. Of the eight patients, who attained pCR in the 
breast and axilla, three patients (38%) experienced relapse as 
compared with 26 of the 56 patients (46%) with less than pCR. 
The same three patients were the only patients who 
experienced relapse among all 13 patients with pCR in the 
breast. Of the seven patients, who received neoadjuvant 
trastuzumab, only one developed regional and distant relapse 
after 27 months. The median PFS for the series was 48 months 
(95% CI, 20–76 months) and the five-year PFS rate (±SE) was 
48% (±7%). 
In a univariate analysis, the following variables prognosticated 
poor PFS and were subsequently tested in a multivariate model: 
age • 35 years (p = 0.08); ER negative tumour (p = 0.07); 
tumour grade III (p = 0.001); pathologically positive lymph node 
(p = 0.008); extra-nodal extension (p = 0.07); and higher scoring 
system (p = 0.006) according to that proposed by Jeruss et al 
[7]. For the latter variable, we defined three distinctive risk 
groups (low-risk = 1–2 score, intermediate-risk = 3 score, and 
high-risk = 4–5 score). The Cox proportional hazards model 
identified higher score in the scoring system as the only variable 
that independently influenced PFS (p = 0.006) (Table 4 and 
Figure 1). 
The median OS has not been reached (Figure 2); however, the 
estimated five-year OS (±SE) was 68% (±9%). Disease-related 
mortality occurred in two of the eight patients who attained pCR 
in the breast and axilla. However, none of those who received 
neoadjuvant trastuzumab have died. In a univariate analysis, 
the following variables predicted poor OS and were 
subsequently tested in a multivariate model: tumour grade III (p 
= 0.02); ER- (p = 0.014); PR- (p = 0.03); lymphovascular
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Table 4: Multivariate analysis of prognostic variables for progression-free (PFS) and overall survival (OS) 
 
 
Figure 1: Kaplan-Meier estimates of progression-free survival of patients stratified into three risk groups according to the combined scoring 
system.
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Figure 2: Kaplan-Meier estimate of overall survival.
invasion (p = 0.07); less than pCR (p = 0.06) and extra-nodal 
extension (p = 0.01). The scoring system showed no prognostic 
significance, and only ER negative tumours and the presence of 
lymphovascular space invasion were associated with an 
independent adverse effect on OS (Table 4). 
PST was well tolerated with the expected treatment-related 
toxicity. There was no incidence of therapy-related mortality and 
no patient developed secondary malignancy other than 
contralateral breast cancer in three patients. 
 
Discussion 
Patients with LABC do very poorly when treated by locoregional 
therapy alone. Such therapy favourably affects locoregional 
control, but most relapses are due to the development of distant 
metastases [24,25]. However, while PST regimens have been 
shown to have a favourable effect on the outcome of patients 
with LABC, the survival advantage of primary chemotherapy is 
yet to be shown [26–28]. 
In this series, there was significant prevalence of poor 
clinicopathologic features among patients. Nevertheless, PST 
achieved a significant downstaging of the primary tumour size 
and the clinical nodal status resulting in a high-clinical response 
rate of 76%, of which 28% was complete. However, only 20% 
and 28% of patients demonstrated pCR and microscopic 
residual invasive tumour, respectively. Moreover, of the 62 
patients with known nodal status, 22 (35%) had negative axillary 
lymph nodes and, of those, eight patients (13%) had pCR in the 
breast and the axilla. 
The regression model showed that ER negativity was the only 
variable that predicted pCR in the primary tumour. That finding 
is consistent with other published series that have shown that 
ER negative tumours tend to have a higher pathologic response 
rate to chemotherapy than ER positive disease [29–32]. 
Despite only seven patients with HER-2+ tumours receiving 
trastuzumab, three patients (45%) attained pCR in the primary 
tumour and the axilla. The achieved results are consistent with 
published studies. Incorporating trastuzumab with 
chemotherapy in the neoadjuvant setting in HER-2 over-
expressing disease has uniformly demonstrated impressive 
pCR rate ranging from 39% to 67% [33–35]. 
At a median follow-up of 42 months (95% CI, 34–49 months), 
disease recurrence was documented in 45% of patients. The 
five-year PFS was 48%, and the median PFS was 48 months. 
Three of the seven patients who attained pCR in breast and 
axilla had relapsed. Reported series have shown a five-year 
recurrence rate in patients with a pCR ranging from 13% to 35% 
[3,36,37]. The five-year OS was projected as 68%, which is 
somewhat inferior to that reported in other series [38,39]; 
however, the attained OS was expected considering the poor 
clinicopathologic features of patients. 
Interestingly, while the combined scoring system was developed 
on older patients with less advanced locoregional disease [7]; in 
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our patients, the system was the only variable that distinctly 
classified patients into three risk groups with significantly 
different PFS rates. The scoring system, however, did not 
prognosticate OS. The lack of a prognostic effect of the scoring 
system on OS may be related to the few number of events. On 
the other hand, the Cox model identified ER tumour and the 
presence of lymphovascular space invasion as independent 
adverse prognostic variables for OS. In a large, recently 
published series, lymphovascular space invasion was a strong 
independent variable that predicted higher locoregional failure 
among patients with LABC [40]. 
The current series has several limitations. First, the series was 
relatively small; however, the series included a group of patients
that largely had poor clinicopathologic characteristics. Second, 
various PST regimens have been used; however, all patients 
were offered the most active PST agents and received a 
uniform management strategy at a single institution. 
In conclusion, this study described the clinical and pathological 
features, management strategy and outcome of young patients 
with LABC in a developing country. The study also identified 
predictor and prognostic variables that could influence outcome 
in a similar patient population. The prognosis of LABC remains 
guarded. The aggressive nature of LABC and the ability to 
measure drug effect in vivo indicate that more clinical trials of 
combining existing and newer biological agents with 
chemotherapy are needed [41,42]. 
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